34 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
13 Sep 23
Notice of Annual General Meeting of Shareholders
4:42pm
, an access code and additional information regarding the Meeting from the member of the TASE and after carrying out a secured identification process
6-K
EX-10.1
ENLV
Enlivex Therapeutics Ltd
30 Dec 22
Report of Foreign Private Issuer
4:02pm
of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance … Data, and Personal Data and to the protection of such IT Systems, Confidential Data, and Personal Data from unauthorized use, access
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
5 Oct 22
Notice of Annual General Meeting of Shareholders
3:00pm
) electronically via the electronic voting system of the Israel Securities Authority (the “ISA”) after receiving a personal identifying number, an access code
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
12 Sep 22
Report of Foreign Private Issuer
8:02am
and latest advances in oncology; and (3) promote equal access to optimal cancer care for all patients.
ABOUT ALLOCETRA™
Allocetra™ is being developed
6-K
EX-99.1
178 soml8
30 Sep 21
Annual and Extraordinary General Meeting of Shareholders
8:01am
6-K
EX-1.1
dk80apmh35096 17t
12 Feb 21
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares
5:17pm
6-K
EX-10.1
5rez 3t3lhwlhxsp
22 Oct 20
Report of Foreign Private Issuer
8:47am
6-K
c9avnosu8uc1ktdoic6
15 Jun 20
Report of Foreign Private Issuer
6:55am
6-K
EX-99.1
0yc 24t1k7l5xcu
19 May 20
Annual and Extraordinary General Meeting of Shareholders
8:04am
6-K
EX-1.1
2ocxzq9g rfs
5 Mar 20
Report of Foreign Private Issuer
8:16am
6-K
EX-1.1
gw0a8fk
26 Feb 20
Enlivex Therapeutics Closes $8.0 Million Registered Direct Offering
4:15pm
20-F/A
3huybkdyaixyel du8yr
23 Jan 20
Annual report (foreign) (amended)
4:31pm